logo

For the Inventor, By the Inventor

Gaithersburg, MD, United States of America

Genvec, Inc.


USPTO Granted Patents = 88

% Expired Patents = 13.6



Forward Citations = 1,794

Loading Chart...
Loading Chart...

43 inventors (with patents filed for the assignee):

goldMedal Douglas E Brough (54 out of 58 patents)

silverMedal Imre Kovesdi (54 out of 58 patents)

bronzeMedal Duncan L McVey (37 out of 41 patents)

4.  Joseph T Bruder (21 out of 25 patents)

5.  Jason G D Gall (18 out of 20 patents)

6.  Thomas J Wickham (18 out of 19 patents)

7.  Petrus W Roelvink (10 out of 12 patents)

8.  C Richter King (8 out of 24 patents)

9.  Lisa Wei (5 out of 5 patents)

10.  Jason Gall (5 out of 8 patents)

11.  Alena Lizonova (5 out of 5 patents)

12.  Marilyn Menger (5 out of 5 patents)

13.  Damodar R Ettyreddy (4 out of 6 patents)

14.  Ping Chen (4 out of 4 patents)

15.  Miguel E Carrión (4 out of 4 patents)


Core Competencies:
Adenoviral Vectors
Gene Transfer
Malaria Vaccines
Herpes Simplex Virus
Therapeutic Regimen
Replication Deficient
Chimeric Vectors
Transgene Persistence
Viral Vector Library
Inhibitory Gene Products
Fluorescence Detection
Eukaryotic Viral Vectors

88 patents:

1. 11359214 - Simian (gorilla) adenovirus or adenoviral vectors and methods of use (2022-06-14),
2. 11279951 - Adenoviral vector encoding human atonal homolog-1 (HATH1) (2022-03-22),
3. 11155832 - Adenovectors for delivery of therapeutic genetic material into T cells (2021-10-26),
4. 11034975 - Affenadenovirus (gorilla) or adenoviral vectors and methods of use (2021-06-15),
5. 10947560 - Modified serotype 28 adenoviral vectors (2021-03-16),
6. 10792376 - Affenadenovirus (gorilla) or adenoviral vectors and methods of use (2020-10-06),
7. 10787682 - Simian (gorilla) adenovirus or adenoviral vectors and methods of use (2020-09-29),
8. 10780153 - Malaria antigens and methods of use (2020-09-22),
9. 10640776 - Method for propagating adenoviral vectors encoding inhibitory gene products (2020-05-05),
10. 10314901 - Malaria antigens and methods of use (2019-06-11),
11. 10272162 - Affenadenovirus (gorilla) or adenoviral vectors and methods of use (2019-04-30),
12. 10260074 - Affenadenovirus (gorilla) or adenoviral vectors and methods of use (2019-04-16),
13. 10125174 - Herpes simplex virus vaccine (2018-11-13),
14. 10059962 - Simian (gorilla) adenovirus or adenoviral vectors and methods of use (2018-08-28),
15. 10022432 - Malaria antigens and methods of use (2018-07-17),
Company Overview
Genvec, Inc., based in Gaithersburg, MD, specializes in the development of adenoviral vectors for gene transfer applications. The company focuses on innovative therapeutic regimens, particularly in the fields of malaria vaccines and herpes simplex virus treatments. Genvec's expertise includes the creation of replication-deficient and chimeric vectors, which enhance transgene persistence and efficacy. Through its advanced technologies, Genvec aims to address significant medical challenges and contribute to the advancement of gene therapy solutions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Genvec, Inc. USPTO Patent Assignee Logo
88 Patents

#2 in Gaithersburg, MD

#37 in Maryland

#4,240 in US

#8,693 in the World

Gaithersburg, MD (US)
Gaithersburg, MD, United States of America

Genvec, Inc.

Forward Citations = 1,794

43 inventors:

goldMedal Douglas E Brough (54 out of 58 patents)

silverMedal Imre Kovesdi (54 out of 58 patents)

bronzeMedal Duncan L McVey (37 out of 41 patents)

4.  Joseph T Bruder (21 out of 25 patents)

5.  Jason G D Gall (18 out of 20 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Genvec, Inc.. Retrieved from https://idiyas.com/company/genvec

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…